Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Methionine aminopeptidase 2 (MetAP2) is a cytosolic metalloenzyme that catalyzes the hydrolytic removal of N-terminal methionine from newly synthesized proteins, a post-translational modification essential for proper protein maturation and function. It is a target for antiangiogenic drugs due to its role in endothelial cell proliferation and angiogenesis, particularly in cancer therapy. Overexpression is observed in some cancers and may play a role in fibrotic diseases. Natural products like fumagillin and ovalicin are potent inhibitors of MetAP2.
Inhibition of MetAP2 enzymatic activity, leading to suppression of angiogenesis and cell proliferation.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Methionine Aminopeptidase 2.